Prognostic value of left ventricular hypertrophy assessed with 15O-water positron emission tomography
Clicks: 1
ID: 319586
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #23 of 47 articles by views in European Heart Journal - Imaging Methods and Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Left ventricular (LV) hypertrophy is associated with adverse cardiac outcomes. LV mass index (LVMi) and interventricular septal wall thickness (WT) can be derived from 15O-water positron emission tomography (PET), but their prognostic value is unknown. We aimed to assess the prognostic value and test-retest repeatability of PET-derived LV hypertrophy metrics in patients evaluated for suspected coronary artery disease (CAD). Methods and Results We retrospectively included 783 consecutive patients referred for rest-stress PET. LVMi and WT were determined on non-ECG-gated resting 15O-water PET scans. Subjects were stratified by previous heart failure (HF) diagnosis and patients with known hypertrophic/infiltrative cardiomyopathy were excluded. The primary outcome was major adverse cardiac events (MACE: cardiovascular death or acute HF). The prognostic value of LV hypertrophy measurements was evaluated using Cox hazard ratios (HR [95% confidence interval]). Test-retest repeatability was evaluated in prospective data from 21 patients with repeated PET scans. Patients with known HF but no hypertrophic/infiltrative cardiomyopathy (18%) had significantly higher LVMi (p<0.0001) and WT (p=0.0015) compared to subjects without HF (82%). Among patients without HF, 30 experienced MACE during a median 3.8 year follow up. Both LVMi (HR 1.04 [1.02-1.06] per g/m2, p<0.0001) and WT (HR 1.36 [1.10-1.68] per mm, p=0.0045) independently predicted MACE after adjustment for sex, age and myocardial flow reserve. Test-retest repeatability was high, with no significant bias. Conclusion PET LV hypertrophy metrics can be robustly quantified from routine 15O-water PET and provide prognostic information beyond myocardial perfusion.
| Reference Key |
openalex_W7167236428
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jonathan Sigfridsson, Patrik Svanström, Tanja Kero, Hendrik J Harms, Jonny Nordström, Mark Lubberink, Jens Stilhoff Sörensen |
| Journal | European Heart Journal - Imaging Methods and Practice |
| Year | 2026 |
| DOI |
10.1093/ehjimp/qyag121
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.